MedTrace Logo

A Clinical Study to Assess the Efficacy and Safety of DA-3002

NCT01813630 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2018-07-26

No results posted yet for this study

Summary

A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.

Conditions

  • Turner's Syndrome

Interventions

DRUG

DA-3002

DRUG

Genotropin®

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Han Wook Yoo, M.D., Ph.D. · Asan Medical Center

  • Byung Kyu Suh, M.D., Ph.D. · Seoul St. Mary's Hospital, The Catholic University of Korea

  • Cheol Woo Ko, M.D., Ph.D. · Kyungpook National University Hospital

  • Kee Hyoung Lee, M.D., Ph.D. · Korea University Anam Hospital

  • Dong Kyu Jin, M.D.,Ph.D. · Seoul Medical Center

  • Choong Ho Shin, M.D., Ph.D. · Seoul National University Hospital

  • Jin Soon Hwang, M.D., Ph.D. · Aju University Hospital

  • Ho Seong Kim, M.D., Ph.D. · Severance Children's Hospital Yonsei University

  • Woo Young Jeong, M.D., Ph.D. · Pusan University Hospital

  • Chang Jong Kim, M.D., Ph.D. · Chonnam National University Hospital

  • Heon Suk Han, M.D., Ph.D. · Chungbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01813630 on ClinicalTrials.gov